LONDON--AstraZeneca PLC (AZN.LN) Friday said a key committee of the European Medicines Agency had issued an opinion recommending approval of "saxa/dapa" tablets for treating adults with Type-2 diabetes.

The bio-pharmaceutical company said the positive opinion from the Committee for Medicinal Products for Human Use would now be reviewed by the European Commission, which holds the power to approve medicines for the European Union.

Saxa/dapa is a fixed-dose combination of saxagliptin and dapagliflozin, the company said.

Shares at 1145 GMT were down 43.50 pence, or 1.1%, at 3968 pence, valuing the company at 50.17 billion pounds ($73.72 billion).

Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga

(END) Dow Jones Newswires

May 27, 2016 08:27 ET (12:27 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Astrazeneca Charts.